Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study

[1]  J. McGill,et al.  Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study. Reply to Chantelau E [letter] and Currie CJ [letter] , 2009, Diabetologia.

[2]  I. Hirsch,et al.  Insulin glargine and cancer--an unsubstantiated allegation. , 2009, Diabetes technology & therapeutics.

[3]  L. Smeeth,et al.  Insulin glargine and malignancy: an unwarranted alarm , 2009, The Lancet.

[4]  E. Chantelau.  Diabetic retinopathy and insulin glargine , 2009, Diabetologia.

[5]  C. Currie,et al.  The longest ever randomised controlled trial of insulin glargine: study design and HbA1c findings , 2009, Diabetologia.

[6]  J. McGill,et al.  Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study , 2009, Diabetologia.

[7]  R. Holman,et al.  10-year follow-up of intensive glucose control in type 2 diabetes. , 2008, The New England journal of medicine.

[8]  G. Bolli,et al.  Beyond the era of NPH insulin--long-acting insulin analogs: chemistry, comparative pharmacology, and clinical application. , 2008, Diabetes technology & therapeutics.

[9]  A. Rolla.  Pharmacokinetic and pharmacodynamic advantages of insulin analogues and premixed insulin analogues over human insulins: impact on efficacy and safety. , 2008, The American journal of medicine.

[10]  D. Mayer,et al.  Proliferative effects of insulin analogues on mammary epithelial cells , 2008, Archives of physiology and biochemistry.

[11]  D. Roith.  Insulin glargine and receptor-mediated signalling: clinical implications in treating type 2 diabetes. , 2007 .

[12]  D. Owens,et al.  Comparison of Pharmacokinetics and Dynamics of the Long-Acting Insulin Analogs Glargine and Detemir at Steady State in Type 1 Diabetes , 2007, Diabetes Care.

[13]  P. Mullins,et al.  Negative binomial meta-regression analysis of combined glycosylated hemoglobin and hypoglycemia outcomes across eleven Phase III and IV studies of insulin glargine compared with neutral protamine Hagedorn insulin in type 1 and type 2 diabetes mellitus. , 2007, Clinical therapeutics.

[14]  F. Ferris,et al.  Early retinopathy progression in four randomized trials comparing insulin glargine and Nph insulin , 2007 .

[15]  M. Kellerer,et al.  Comparison of the Mitogenic Potency of Regular Human Insulin and its Analogue Glargine in Normal and Transformed Human Breast Epithelial Cells , 2007, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[16]  G. Peterson.  Intermediate and long-acting insulins: a review of NPH insulin, insulin glargine and insulin detemir , 2006, Current medical research and opinion.

[17]  P. Aschner,et al.  Therapy in type 2 diabetes: insulin glargine vs. NPH insulin both in combination with glimepiride. , 2006, Archives of medical research.

[18]  H. Yki-Järvinen,et al.  Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study , 2006, Diabetologia.

[19]  Patrik Rorsman,et al.  Glucose-sensing mechanisms in pancreatic β-cells , 2005, Philosophical Transactions of the Royal Society B: Biological Sciences.

[20]  P. Home,et al.  A randomized multicentre trial of insulin glargine compared with NPH insulin in people with type 1 diabetes , 2005, Diabetes/metabolism research and reviews.

[21]  H. Arnqvist,et al.  Insulin-like growth factor I receptors are more abundant than insulin receptors in human micro- and macrovascular endothelial cells. , 2004, American journal of physiology. Endocrinology and metabolism.

[22]  J. Rosenstock,et al.  The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. , 2003, Diabetes care.

[23]  A. Fritsche,et al.  Glimepiride Combined with Morning Insulin Glargine, Bedtime Neutral Protamine Hagedorn Insulin, or Bedtime Insulin Glargine in Patients with Type 2 Diabetes , 2003, Annals of Internal Medicine.

[24]  M. Ziemen,et al.  A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes. , 2003, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[25]  Matthew D. Davis,et al.  Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. , 2002, JAMA.

[26]  B. Zinman,et al.  Insulins today and beyond , 2001, The Lancet.

[27]  J. Rosenstock,et al.  Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. , 2001, Diabetes care.

[28]  Stephen J. Aldington,et al.  UKPDS 50: Risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis , 2001, Diabetologia.

[29]  H. Yki-Järvinen,et al.  Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. , 2000, Diabetes care.

[30]  L. Schäffer,et al.  Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. , 2000, Diabetes.

[31]  I. Hirsch,et al.  Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S. Study Group of Insulin Glargine in Type 1 Diabetes. , 2000, Diabetes care.

[32]  R. Holman,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .

[33]  Uk-Prospective-Diabetes-Study-Group.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) , 1998, The Lancet.

[34]  J. Eckel,et al.  Growth promoting and metabolic activity of the human insulin analogue [GlyA21,ArgB31,ArgB32]insulin (HOE 901) in muscle cells. , 1997, European journal of pharmacology.

[35]  S. Genuth,et al.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.

[36]  F. Ferris,et al.  Photocoagulation for diabetic macular edema. , 1987, Archives of ophthalmology.

[37]  R. Beck,et al.  Early retinopathy progression in four randomized trials comparing insulin glargine and NPH [corrected] insulin. , 2007, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[38]  The effect of intensive diabetes treatment on the progression of diabetic retinopathy in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial. , 1995, Archives of ophthalmology.

[39]  Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. The Diabetes Control and Complications (DCCT) Research Group. , 1995, Kidney international.

[40]  Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Early Treatment Diabetic Retinopathy Study Research Group. , 1991, Ophthalmology.

[41]  Grading diabetic retinopathy from stereoscopic color fundus photographs--an extension of the modified Airlie House classification. ETDRS report number 10. Early Treatment Diabetic Retinopathy Study Research Group. , 1991, Ophthalmology.

[42]  Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. , 1985, Archives of ophthalmology.